AAM
NVCR icon

Advisors Asset Management’s NovoCure NVCR Stock Holding History

Advisors Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-887
Closed -$26.4K – 1530
2024
Q4 		$26.4K Sell
887
-45
-5% -$952 ﹤0.01% 1366
2024
Q3 		$14.6K Sell
932
-17
-2% -$308 ﹤0.01% 1393
2024
Q2 		$16.3K Sell
949
-105
-10% -$1.85K ﹤0.01% 1384
2024
Q1 		$16.5K Hold
1,054
– – ﹤0.01% 1373
2023
Q4 		$15.7K Sell
1,054
-111
-10% -$1.49K ﹤0.01% 1368
2023
Q3 		$18.8K Buy
+1,165
New +$33.6K ﹤0.01% 1364
2023
Q2 		– Sell
-3,729
Closed -$224K – 1449
2023
Q1 		$224K Sell
3,729
-1,361
-27% -$109K ﹤0.01% 1093
2022
Q4 		$373K Sell
5,090
-8,203
-62% -$617K 0.01% 1000
2022
Q3 		$1.01M Sell
13,293
-278
-2% -$21.7K 0.02% 719
2022
Q2 		$943K Sell
13,571
-280
-2% -$21.1K 0.02% 774
2022
Q1 		$1.15M Sell
13,851
-12,665
-48% -$933K 0.02% 764
2021
Q4 		$1.99M Sell
26,516
-3,576
-12% -$359K 0.03% 609
2021
Q3 		$3.5M Sell
30,092
-5,974
-17% -$903K 0.05% 392
2021
Q2 		$8M Sell
36,066
-2,434
-6% -$473K 0.12% 166
2021
Q1 		$5.09M Sell
38,500
-3,702
-9% -$586K 0.08% 246
2020
Q4 		$7.3M Sell
42,202
-831
-2% -$114K 0.12% 157
2020
Q3 		$4.79M Sell
43,033
-11,339
-21% -$907K 0.09% 212
2020
Q2 		$3.22M Sell
54,372
-13,603
-20% -$895K 0.06% 312
2020
Q1 		$4.58M Buy
67,975
+1,963
+3% +$155K 0.11% 186
2019
Q4 		$5.56M Sell
66,012
-12,758
-16% -$1.03M 0.1% 242
2019
Q3 		$5.89M Buy
78,770
+1,634
+2% +$131K 0.11% 227
2019
Q2 		$4.88M Buy
77,136
+5,115
+7% +$259K 0.09% 274
2019
Q1 		$3.47M Buy
72,021
+13,160
+22% +$633K 0.06% 361
2018
Q4 		$1.97M Buy
58,861
+18,383
+45% +$672K 0.04% 507
2018
Q3 		$2.12M Buy
40,478
+28,825
+247% +$1.15M 0.03% 586
2018
Q2 		$365K Buy
+11,653
New +$324K 0.01% 1125

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Advisors Asset Management's NVCR Position: Q1 2025 in Review

Advisors Asset Management sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 887 shares — an estimated $26.4K sold.

Advisors Asset Management first reported a position in NVCR in Q2 2018 and held it in 26 quarters. The position peaked at $8M in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Advisors Asset Management reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Advisors Asset Management sold 887 NovoCure shares in Q1 2025, an estimated $26.4K.
  • Advisors Asset Management first reported a position in NovoCure in Q2 2018 and held it in 26 quarters.
  • Advisors Asset Management's NovoCure position peaked at $8M in Q2 2021.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Advisors Asset Management's 13F filing for Q1 2025, filed 15 May 2025.